U.S. Markets open in 38 mins
  • S&P Futures

    4,704.00
    +2.50 (+0.05%)
     
  • Dow Futures

    35,830.00
    +19.00 (+0.05%)
     
  • Nasdaq Futures

    16,494.75
    +13.50 (+0.08%)
     
  • Russell 2000 Futures

    2,365.40
    +1.20 (+0.05%)
     
  • Gold

    1,861.20
    -0.20 (-0.01%)
     
  • Silver

    24.88
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1369
    -0.0006 (-0.0568%)
     
  • 10-Yr Bond

    1.5890
    -0.0150 (-0.94%)
     
  • Vix

    17.59
    +0.48 (+2.81%)
     
  • GBP/USD

    1.3497
    -0.0003 (-0.0216%)
     
  • USD/JPY

    114.3040
    +0.0520 (+0.0455%)
     
  • BTC-USD

    58,258.82
    +833.66 (+1.45%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     
  • FTSE 100

    7,255.96
    -35.24 (-0.48%)
     
  • Nikkei 225

    29,683.09
    +84.43 (+0.29%)
     

Celsion's Vaccine Platform Shows Potential Against COVID-19 In Preclinical Studies

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Celsion Corporation (NASDAQ: CLSN) has announced results from preclinical in vivo studies of its next-generation PLACCINE DNA vaccine platform.

  • Data showed that the vaccine candidate produced antibodies and cytotoxic T-cell response specific to the spike antigen of SARS-CoV-2 in animal models.

  • The antibodies to the SARS-CoV-2 spike antigen prevented the infection of cultured cells in a viral neutralization assay.

  • The production of antibodies predicts the ability of PLACCINE to protect against SARS-CoV-2 exposure, and the elicitation of cytotoxic T-cell response shows the vaccine's potential to eradicate cells infected with SARS-CoV-2.

  • Celsion expects to report these data at the International Vaccines Conference to be held in October.

  • The Company plans to file an Investigational New Drug application with the FDA by early 2022.

  • Price Action: CLSN stock is up 2.91% at $1.06 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.